Diadema Partners LP Neurocrine Biosciences Inc Transaction History
Diadema Partners LP
- $383 Billion
- Q1 2025
A detailed history of Diadema Partners LP transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Diadema Partners LP holds 62,247 shares of NBIX stock, worth $7.53 Million. This represents 1.8% of its overall portfolio holdings.
Number of Shares
62,247Holding current value
$7.53 Million% of portfolio
1.8%Shares
1 transactions
Others Institutions Holding NBIX
# of Institutions
652Shares Held
97.2MCall Options Held
749KPut Options Held
553K-
Black Rock Inc. New York, NY14.2MShares$1.72 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.94MShares$1.2 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.53MShares$670 Million0.37% of portfolio
-
State Street Corp Boston, MA4.86MShares$588 Million0.02% of portfolio
-
Jpmorgan Chase & CO New York, NY2.67MShares$323 Million0.02% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $11.6B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...